Form D · Biotechnology
Appili Therapeutics Inc.
Halifax, A5 · CIK 0001693581
Offering snapshot reported Sep 2, 2021 · SEC filing
- Reported sold
- $3.5M Offering amount: $3.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 18, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 2, 2021 | Initial | $3,500,000 | No comparison | 1 | SEC filing |
| Jun 24, 2020 | Initial | $1,021,025 | No comparison | 2 | SEC filing |
| Dec 30, 2016 | Initial | $14,739 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-412097
Source: Form D, filed Sep 2, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Armand Balboni | Director, Executive |
| Brian M. Bloom | Director |
| Juergen Froehlich | Director |
| John Holyoake | Director, Executive |
| Lidija Marusic | Director |
| Theresa Matkovits | Director |
| Ian C. Mortimer | Director |
| Rochelle Stenzler | Director |
| Kimberly D. Stephens | Executive |
| Kevin Sullivan | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
21 1344 Summer St.
Halifax, A5, B3H 0A8
Halifax, A5, B3H 0A8